Xarelto is part of a new class of drugs referred to as new oral anti-coagulants (noacs). These drugs may be prescribed to patients with atrial fibrillation to the risk of clot or stroke or to reduce the risk of deep-vein thrombosis, or pulmonary embolism, especially following knee or hip replacement surgery. Some patients who take Xarelto suffer potentially life-threatening side effects, including severe gastrointestinal or intracranial bleeding The claims against Xarelto involve failure to adequately warn physicians of the risks and instruct physicians as to the appropriate use of the drug. Plaintiffs are claiming in part that many bleeds suffered by people on the drug could have been prevented. (You should never start or stop taking a prescribed drug without consulting your physician.)
New oral anti-coagulants, Xarelto.